secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0001664710-25-000015
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Therapeutics Q4 2024 net loss $46.0M; receives $200M Takeda upfront for elritercept
--------------------------------------------------------------------------------

- Net loss of $46.0M in Q4 2024 vs $40.2M in Q4 2023; full-year net loss $187.4M.
- Revenue of $3.0M in Q4 2024 vs $0.1M in prior period, largely from Hansoh milestone.
- Cash and equivalents $559.9M at Dec 31, 2024; plus $200M Takeda upfront payment received Feb 2025 extends runway into 2029.
- Phase 1 data for KER-065 expected in Q1 2025; Phase 2 TROPOS trial data for cibotercept (KER-012) planned.
- R&D expenses rose to $45.6M in Q4 2024, driven by elritercept Phase 3 and TROPOS trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000015/0001664710-25-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000015/kros-20250226.htm
  HTML page:      https://secwatch.observer/filing/0001664710-25-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer